News & Reports

pharmaceutical injectors for insulin or GLP-1s in production

The Cold Storage Glut Is Real. Pharma-Grade Capacity Is Still Tight.

Why Life Sciences Manufacturers Should Not Read the Oversupply Headlines as Their Story The cold storage industry is working through an oversupply. After a speculative construction boom that added roughly 14.5% capacity between 2021 and 2025,…
insulated door leading into a cold storage room

Why Euro-American Invests in the Future of Pharmaceutical Logistics

Building for What Comes Next The pharmaceutical supply chain of 2026 does not look like the pharmaceutical supply chain of even five years ago. The products are more complex, more temperature-sensitive, and more tightly regulated. The trade…
cargo ship being assisted by a tugboat while arriving in port

Reshoring Pharma Does Not Eliminate Global Logistics. It Changes It.

The headlines are striking. Reuters reported in August 2026 that major global pharmaceutical companies have announced more than $500 billion in combined U.S. manufacturing, research, and supply chain investment commitments. The list of companies…

Lab Vacancy Is Rising. Compliant Storage Capacity Is Not.

What the 2026 Life Sciences Real Estate Rebound Actually Means for Manufacturers Who Need Storage Space Cushman & Wakefield's February 2026 Life Sciences Update reported global lab and cGMP rents softening 1.7 percent year over year, with…

“FDA Registered” Is Not a Complete Import Readiness Check

On July 13, 2026, FDA updated the import alert covering drugs and medical devices from firms without valid registration and listing. FDA's import alert database is updated in real time, and products identified under this alert may be subject…

Integrated Does Not Always Mean Accountable: How to Evaluate a Life Sciences Logistics Network

The pharmaceutical cold chain logistics market is consolidating quickly. A July 20, 2026 review from Pharmaceutical Commerce documented a wave of investment and integration across the sector: new facilities, new service lines, and new technology…

The Brazil Tariff Is Not a Yes or No Question: A Practical Guide for Pharmaceutical and Medical Product Importers

On July 15, 2026, the Office of the U.S. Trade Representative issued its final Section 301 action on Brazil. The action imposes an additional 25% duty on covered Brazilian origin goods entered for consumption, or withdrawn from warehouse for…

FDA Import Compliance for Pharmaceutical and Biologics Importers: A Practical Guide

More than 85 percent of the brand-name pharmaceuticals dispensed in the United States are manufactured overseas, and the active pharmaceutical ingredients, biologic drug substances, and finished products that supply the American market cross…
view down the aisle of a cold storage warehouse full of goods

Build, Expand, or Outsource? The Strategic Case for Outsourced GMP Storage in Life Sciences Manufacturing

Pharmaceutical, biotech, and medical device manufacturers all reach the same operational moment. Inventory volumes have grown. A commercial launch is approaching. A new supplier has been qualified. An existing facility is running at capacity.…
stern view of a cargo ship

The New Sourcing Map for U.S. Importers in 2026

Three years ago, the “China+1” strategy, maintaining Chinese sourcing while adding at least one alternative country to reduce concentration risk, was an emerging concept being discussed in board rooms. Today it is the operational baseline…
air freight prepped to be loaded into a plane

Air Cargo at 33% Above Year-Ago Rates: What Pharmaceutical Cold Chain Shippers Are Doing About It

Air cargo rates have not normalized. According to the World ACD weekly air cargo report, global air cargo spot rates were running approximately 33% above year-ago levels through June 7, 2026, with sharper regional pressure on lanes most directly…
various packaged medications on top of an Indian flag

India’s Emergence as the Leading Pharmaceutical Sourcing Alternative: What Life Sciences Importers Need to Know in 2026

The pharmaceutical industry’s effort to diversify sourcing away from China has matured. According to recent industry data, nearly 79% of companies have moved at least some sourcing volume away from China, and India has emerged as the leading…
vaccine production line

Section 232 Pharmaceutical Tariffs: What Life Sciences Importers Must Do Before July 31, 2026

The April 2, 2026 presidential proclamation imposing Section 232 tariffs on patented pharmaceutical imports did not give the life sciences industry much time to prepare. For covered importers, branded drug manufacturers, biologics CDMOs, specialty…

The Strategic Advantage of Local: How Proximity to Massachusetts’ Life Sciences Hub Accelerates Your Supply Chain

Modern life sciences supply chains demand more than movement. They demand velocity, compliance, and resilience — the ability to move products quickly, safely, and without regulatory interruption, regardless of what is happening in the broader…

Transfer Pricing and Customs Valuation: What Importers Need to Know About CBP Audit Risk

A large and growing share of U.S. imports involve transactions between related parties — a U.S. subsidiary purchasing goods from its foreign parent, an American manufacturer sourcing from an affiliated overseas plant, a distributor buying…

Global PMI Update: What April 2026 Manufacturing Data Tells Us About Global Supply Chain Risk

The Global Purchasing Managers’ Index is one of the most closely watched leading indicators in international trade. It captures manufacturing conditions in real time across dozens of countries — translating factory-floor sentiment about…

Future-Proofing Your Pharmaceutical Cold Chain

Building a Compliant, Scalable Cold Chain from Clinical to Commercial The pharmaceutical cold chain has never been more demanding. Biologics, monoclonal antibodies, GLP-1 therapies, and an expanding pipeline of temperature-sensitive products…

International Supply Chain Update: Tariff Hearings, Freight Market Data, and Middle East Disruption — April 2026

International supply chains are navigating simultaneous pressure from two directions: a tariff policy transition that will reshape duty exposure for importers across dozens of countries, and the ongoing ripple effects of Middle East conflict…

CBP’s New CAPE System Is Live: What Importers Need to Know About IEEPA Duty Refunds

Background: Why IEEPA Refunds Are Available On February 20, 2026, the U.S. Supreme Court ruled that the International Emergency Economic Powers Act (IEEPA) does not authorize the President to impose tariffs. As a result, tariffs collected under…

China vs. Vietnam: A Strategic Comparison of Import Costs for U.S. Businesses

For U.S. importers, the sourcing decision has fundamentally changed. Manufacturing cost alone no longer determines profitability. What matters today is total landed cost — the full picture of duties, tariffs, freight, compliance, and risk…

Understanding Landed Costs: A Practical Guide for U.S. Importers

Every importer knows that the purchase price is not the cost of goods. What determines profitability — what sets the floor for pricing decisions, margin projections, and sourcing strategy — is landed cost: the total, all-in expense of moving…

Customs Clearance Checklist: ISF Filing, Entry Process, and Release Timeline

Customs clearance is not a single event. It is a structured sequence of filings, reviews, and compliance decisions that begins before your cargo is loaded and does not end until duties are paid and your shipment is in your hands. Every step…

How to Start Importing into the United States: A 10-Step Compliance Guide

Most first-time importers underestimate the process. They understand, broadly, that goods need to clear customs. What they often do not anticipate is the sequence of regulatory requirements, documentation obligations, and agency reviews that…

Strait of Hormuz Closure Disrupting Global Supply Chains

Global supply chains continue to face a mix of pricing shifts, infrastructure constraints, and geopolitical uncertainty. While certain cost pressures have eased in early 2026, underlying risks remain—particularly across energy markets, key…